Connect with us

Hi, what are you looking for?

Economy

Peru volunteer who received placebo in Sinopharm vaccine trial dies of COVID-19 pneumonia, university says

The volunteer received the placebo rather than the vaccine.

LIMA — A volunteer who received the placebo in the local Peruvian trial of a coronavirus vaccine produced by China’s Sinopharm Group Co. Ltd. has died from coronavirus disease 2019 (COVID-19)-related pneumonia, the university carrying out the trial said on Tuesday.

Cayetano Heredia University, which is involved with the study, said on the instructions of the Peruvian health regulator it had unblinded the volunteer’s participation in the trial and determined she had received the placebo rather than the vaccine.

“It is important to stipulate that the death of the participant is not related to the vaccine since she received the placebo, and we will therefore report to the relevant regulatory and ethics bodies and maintain the course of this phase three study,” the university said in a statement.

German Malaga, chief researcher at the Cayetano Heredia University, told Reuters by phone that the deceased volunteer had suffered from diabetes.

Mr. Malaga said the trial investigators had so far issued two doses of either the vaccine or placebo to 12,000 volunteers and were now following their responses.

“It is developing without any setbacks. These things can happen, COVID is a disease that causes deaths,” he said.

“Our message to the volunteers is to take care of themselves because we don’t know if they have the vaccine or the placebo,” he added.

The university said in its statement that the volunteer had received “all the necessary care to treat this disease and her complications” and was “fighting for her life” for more than a week.

“It is a painful loss for which we extend our condolences to her family,” the statement added.

In December, Peru temporarily suspended trials of the Sinopharm COVID-19 vaccine due to a “serious adverse event” that occurred with a volunteer in the study.

In Brazil, clinical trials of China’s Sinovac COVID-19 vaccine were suspended before being allowed to resume late last year due to a study subject’s death that was registered in Sao Paulo as a suicide. —  Marco Aquino/Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

JAKARTA — Armed with the world’s largest reserves of nickel and a ban on the export of nickel ore, Indonesia is making itself indispensable...

Economy

LONDON — Britain faces its largest ever strike by health workers on Monday as tens of thousands of nurses and ambulance workers walk out...

Economy

SINGAPORE — Polluting single-use plastic production rose by 6 million tons per year from 2019 to 2021 despite tougher worldwide regulations, with producers making...

Economy

BAMAKO — The Malian interim government on Sunday said the head of the United Nations (UN) peacekeeping mission’s human rights division had 48 hours...

Economy

LVIV — Ukraine has sent letters to companies that back the International Olympic Committee (IOC) urging them to keep Russian athletes out of the...

Economy

SYDNEY — Australian Prime Minister Anthony Albanese will push for bipartisan support on a referendum that aims to set up an Indigenous consultative committee...

You May Also Like

Investing

Browsing history makes referring to sites and pages you’ve visited in the past seamless. It’ll help you recall what page you checked out on...

Investing

The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.